story of the week
Efficacy of Adding Endocrine Therapy to Dual Anti-HER2 Targeted Therapy in Patients With HER2+/HR+ MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer
Breast Cancer Res Treat 2023 Feb 01;198(1)67-74, M Loft, SW Lok, R De Boer, L Malik, S Greenberg, B Yeo, A Anton, M Nottage, V Wong, L Nott, IM Collins, J Torres, F Barnett, JM Lombard, P Gibbs, L GatelyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.